ライフサイエンスコーパス: antiretrovirals

1 ly predicts the combined effects of multiple antiretrovirals.

2 ompared to contemporary clinically-evaluated antiretrovirals.

3 to consider drug-drug interactions with the antiretrovirals.

4 ing cART, without having previously received antiretrovirals.

5 ents with limited or no previous exposure to antiretrovirals.

6 genotypic evaluation of HIV-1 resistance to antiretrovirals.

7 tance to nucleoside (NRTI) and nonnucleoside antiretrovirals.

8 None of the responses were attributable to antiretrovirals.

9 ruses, a goal not easily achieved with other antiretrovirals.

10 t a novel drug target for the development of antiretrovirals.

11 realize the full public health potential of antiretrovirals.

12 and imatinib pharmacokinetics in patients on antiretrovirals.

13 IV infection is successfully controlled with antiretrovirals.

14 ese mutations affect susceptibility to other antiretrovirals.

15 ardiovascular events associated with certain antiretrovirals.

16 findings suggest that nucleoside-containing antiretrovirals administered via recommended protocols d

17 clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify

18 Antiretrovirals alone decreased concentrations of some B

19 Although antiretrovirals alone had no significant effect on ribof

20 Other antiretrovirals and delivery systems are being evaluated

21 ess than 200 copies per mL, or not receiving antiretrovirals and had a CD4 T-cell count of greater th

22 creening, patients were either receiving HIV antiretrovirals and had HIV RNA less than 200 copies per

23 After chemotherapy failure, antiretrovirals and interferon-alpha (IFN-alpha) produce

24 Antiretrovirals and LNSs were given to the mothers from

25 Women were assigned to receive antiretrovirals and LNSs, antiretrovirals only, LNSs onl

26 We used data from the Breastfeeding, Antiretrovirals and Nutrition (BAN) clinical trial (cond

27 d blood spots (DBSs) from the Breastfeeding, Antiretrovirals and Nutrition study to evaluate the impa

28 ontrol arm of the Malawi-based Breastfeeding Antiretrovirals and Nutrition Study using multivariable

29 association between duration of exposure to antiretrovirals and the development of chronic kidney di

30 lood were collected from Children and women: AntiRetrovirals and the Mechanism of Aging (CARMA) cohor

31 Resistance to newer antiretrovirals and to all antiretrovirals in a class wa

32 many source subjects who reported any use of antiretrovirals and was rare among source subjects who r

33 or more antiretrovirals, including screening antiretrovirals, and 169 (15%) had previous virological

34 associated with the use of dideoxynucleoside antiretrovirals, and its development limits the choice o

35 The Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study was undertake

36 ts infected with HIV from the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study.

37 37 women recruited within the Breastfeeding, Antiretrovirals, and Nutrition study at 2 or 6 wk and 24

38 ected Malawian mothers in the Breastfeeding, Antiretrovirals, and Nutrition study were randomly assig

39 The BAN (Breastfeeding, Antiretrovirals, and Nutrition) Study was a randomized c

40 Generic antiretrovirals are currently manufactured at very low p

41 helminths on HIV progression in areas where antiretrovirals are not available.

42 High priced medicines such as antiretrovirals are now included.

43 Antiretrovirals are standard treatment for HIV-1-positiv

44 The adverse effects of antiretrovirals are well characterized and include lacti

45 Antiretrovirals (ARTs) are the cornerstone for treatment

46 prevention research is focused on combining antiretrovirals (ARV) and progestin contraceptives to pr

47 Antiretrovirals (ARVs) affect bone density and turnover,

48 Interactions between antiretrovirals (ARVs) and transplant immunosuppressant

49 Antiretrovirals (ARVs) are used with great success for b

50 Here, we evaluated the detectability of HIV antiretrovirals (ARVs) in hair from a range of drug clas

51 Research and development (R&D) for pediatric antiretrovirals (ARVs) is a lengthy process and lags con

52 s (PrEP) with overlapping and nonoverlapping antiretrovirals (ARVs) on human immunodeficiency virus (

53 rable active ingredients of microbicides are antiretrovirals (ARVs) that directly target viral entry

54 The efficacy of antiretrovirals as postexposure prophylaxis (PEP) to pre

55 The administration of antiretrovirals before HIV exposure to prevent infection

56 known safety profiles of faldaprevir and the antiretrovirals being examined.

57 interactions between antiepileptic drugs and antiretrovirals, but are also problematic as the treatme

58 clinical trials have proven that the use of antiretrovirals by HIV-infected and at-risk uninfected p

59 mproved survival of individuals treated with antiretrovirals, comorbid conditions are increasingly sa

60 ion drug delivery devices delivering topical antiretrovirals could be effective tools in preventing t

61 ns between faldaprevir and the commonly used antiretrovirals darunavir/ritonavir, efavirenz, and teno

62 Use of antiretrovirals dually activity against HBV increased ov

63 Antiretrovirals during early HIV-1 infection modestly de

64 immunosuppressants (e.g., cyclosporine) and antiretrovirals (e.g., protease inhibitors or nonnucleos

65 Little is known about how different antiretrovirals effect inflammation and monocyte activat

66 g the 2013 Controlling the HIV Epidemic With Antiretrovirals evidence summit in London, England, a gr

67 The second Controlling the HIV With Antiretrovirals evidence summit was held 22-24 September

68 As access to antiretrovirals expands under the WHO/Joint United Natio

69 tivirals purposely directed against HHV8 and antiretrovirals for HIV-uninfected people are anticipate

70 hanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) i

71 The efficacy of short-course antiretrovirals for PMTCT in Africa is estimated at 50%.

72 people with HIV to prevent transmission, and antiretrovirals for pre-exposure prophylaxis.

73 The use of antiretrovirals for preexposure prophylaxis (PrEP) among

74 es, including XMRV, and the off-label use of antiretrovirals for the treatment of CFS does not seem j

75 y in HIV type 1-infected women not requiring antiretrovirals for themselves could control maternal vi

76 being considered as partners for long-acting antiretrovirals for use in therapy or prevention of HIV

77 PrEP with antiretrovirals has beneficial effects on early SHIV inf

78 Although antiretrovirals have been noted to favorably alter the c

79 ents treated with anti-TB therapy but not on antiretrovirals (historical control; Group 3).

80 fic factors and outcomes such as exposure to antiretrovirals, HIV progression, hospitalizations, and

81 seroconversion to receive either 36 weeks of antiretrovirals (immediate treatment [IT]) or no treatme

82 sistance to newer antiretrovirals and to all antiretrovirals in a class was uncommon.

83 us one step closer toward using long-acting antiretrovirals in humans.

84 Coadministration of methadone with antiretrovirals in patients with HIV may pose particular

85 l of ART efficacy (Prospective Evaluation of Antiretrovirals in Resource Limited Settings [PEARLS]).

86 articipants of the Prospective Evaluation of Antiretrovirals in Resource-Limited Settings trial, infl

87 ciency virus (HIV)-infected adults receiving antiretrovirals in sub-Saharan Africa.

88 n the immune status following treatment with antiretrovirals, in rare cases the brain can become a ta

89 The number of antiretrovirals included in the ART regimen does not see

90 New studies are evaluating whether different antiretrovirals, including dapivirine, rilpivirine, mara

91 4 (58%) had previously received five or more antiretrovirals, including screening antiretrovirals, an

92 vely stable virus loads before initiation of antiretrovirals, indicating feasibility of assessing HIV

93 Testing for resistance to antiretrovirals is considered to be standard of care and

94 The current management of antiretrovirals is increasingly complex because of the l

95 irus (HIV)-positive patients treated with <3 antiretrovirals is unknown.

96 ions of all vitamins except thiamin, whereas antiretrovirals lowered concentrations of nicotinamide,

97 s that effectively targeting the kidney with antiretrovirals may be critical for patients who are ser

98 Our findings suggest that specific antiretrovirals may potentially impact the risk of futur

99 ovides mechanistic clues to why early use of antiretrovirals may prove beneficial.

100 Here, we show that this choice of antiretrovirals may still cause a bias of pre-integratio

101 %/1%; 87% with HIV RNA <50 copies/mL; 99% on antiretrovirals; median CD4 count: 489 cells/microL; HCV

102 We show that antibodies and antiretrovirals mediate preexposure protection in this m

103 of HIV entry is needed for testing candidate antiretrovirals, microbicides, and vaccines.

104 ney disease was modest, treatment with these antiretrovirals might result in an increasing and cumula

105 eractions between antituberculosis drugs and antiretrovirals needs to be investigated.

106 Despite increasing use of antiretrovirals, no clear reduction in ESLD risk was obs

107 quisition risks, such as approaches based on antiretrovirals, offer promise for controlling the expan

108 n to antiretrovirals, the negative effect of antiretrovirals offset the positive effect of LNSs for a

109 pact of pre-exposure prophylaxis (PrEP) with antiretrovirals on breakthrough HIV or SHIV infection is

110 Long-term effects of antiretrovirals on endothelial function may play an impo

111 ginning treatment, to investigate effects of antiretrovirals on lymphocyte and sperm chromosomes and

112 d individuals; however, the direct effect of antiretrovirals on virus replication in brain parenchyma

113 ssigned to receive antiretrovirals and LNSs, antiretrovirals only, LNSs only, or a control.

114 Patients on potentially nephrotoxic antiretrovirals or at high risk of chronic kidney diseas

115 s not appear to be related to patient use of antiretrovirals or to HIV-1 plasma RNA, cellular RNA, or

116 e measured in 18 patients receiving standard antiretrovirals plus 5-day courses of sc IL-2 (3-18 MIU/

117 chieved controlled release rates of multiple antiretrovirals ranging from mug/d to mg/d by altering t

118 14.0], P = .007), and the number of previous antiretrovirals received (HR = 1.2 per additional drug,

119 cted patients treated early with combination antiretrovirals respond favorably, but not all maintain

120 orded CD4 counts, receipt of prophylaxis and antiretrovirals, sensitivity and specificity of clinical

121 We used data from the Antiretrovirals, Sexual Transmission Risk and Attitudes

122 Long-acting injectable antiretrovirals such as rilpivirine (RPV) could promote

123 ide-based analogues, not normally considered antiretrovirals, such as the anti-herpes drugs Aciclovir

124 slope value among different classes of known antiretrovirals, suggesting a dose-dependent, cooperativ

125 With or without concomitant antiretrovirals, sustained virologic response rates were

126 e virus decrease strongly in the presence of antiretrovirals tenofovir and efavirenz whereas infectio

127 These data support the development of antiretrovirals that antagonize Vif and thereby enable e

128 ment in patients with HIV are needed, as are antiretrovirals that are without vascular risk.

129 results suggest that short-term therapy with antiretrovirals that fail to penetrate the blood-cerebro

130 rotease inhibitors (PI), a critical class of antiretrovirals that will be used in up to 2 million ind

131 ; 24% with previous exposure to short-course antiretrovirals), the median time of follow-up from VS w

132 tiviral activity but, as with small-molecule antiretrovirals, the issues of viral escape and resistan

133 When LNS was given in addition to antiretrovirals, the negative effect of antiretrovirals

134 Because PrEP is based on antiretrovirals, there is considerable concern that it c

135 d benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identif

136 Pre-exposure prophylaxis (PrEP), the use of antiretrovirals to prevent HIV acquisition, has shown pr

137 ic health include male medical circumcision, antiretrovirals to prevent mother-to-child transmission,

138 The use of antiretrovirals to reduce the incidence of human immunod

139 in the Cambodian Early vs Late Initiation of Antiretrovirals trial (CAMELIA) in Cambodia.

140 cohort of HIV-infected pregnant women not on antiretrovirals, urinary CMV shedding was a significant

141 These findings are relevant for optimizing antiretrovirals used for biomedical HIV prevention in wo

142 Many antiretrovirals used in Brazil are produced domestically

143 Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney

144 eatment of HIV-seropositive individuals with antiretrovirals were published in The Lancet in April 19

145 Authorized antiretrovirals were tenofovir, emtricitabine, efavirenz

146 Minimum manufacturing costs of antiretrovirals were US$0.2-$2.1 per gram.

147 The antiretrovirals were zidovudine/lamivudine and nelfinavi

148 ions were then compared with actual costs of antiretrovirals with similar structures.

149 >350 cells/ microL (7 of whom were receiving antiretrovirals) with Haemophilus ducreyi.

150 assays is important, but widening access to antiretrovirals-with or without laboratory monitoring-is

151 aining 101 children) received treatment with antiretrovirals within the first 3 months of life.